<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63631">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737437</url>
  </required_header>
  <id_info>
    <org_study_id>php1</org_study_id>
    <nct_id>NCT01737437</nct_id>
  </id_info>
  <brief_title>Effect of Lidocaine Sprayed on Hemodynamics During Endotracheal Intubation</brief_title>
  <official_title>Effect of Lidocaine Sprayed on Direct Laryngoscopy and Trachea on Hemodynamics During Endotracheal Intubation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A previous study demonstrated topical lidocaine spray on the larynx and the trachea is
      effective in reducing hemodynamic response to laryngoscopy and endotracheal intubation. In
      clinical practice, blind oropharyngeal application of lidocaine without aiding direct
      laryngoscopy can not assured that sprayed lidocaine effectively reaches the larynx and
      trachea. Therefore, direct laryngoscopy should be necessary to reach topical lidocaine to
      correct sites. Unfortunately, direct laryngoscopy itself can affect hemodynamics during
      spraying lidocaine. In this study, we will investigate an effect of lidocaine sprayed on
      direct laryngoscopy and the tracheal mucosa on hemodynamic change throughout intubation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>mean blood pressure, heart rate</measure>
    <time_frame>baseline, at laryngoscope insertion, 60s after laryngoscope insertion, during intubation, one, two, three min after endotracheal intubation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Neurosurgical Patients</condition>
  <arm_group>
    <arm_group_label>group L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% normal saline was applied to trachea and laryngoscope blade in Group C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group LV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10% Lidocaine was applied on laryngoscope blade and trachea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group C</intervention_name>
    <description>0.9% normal saline was applied to trachea and laryngoscope blade</description>
    <arm_group_label>group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group L</intervention_name>
    <description>10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.</description>
    <arm_group_label>group L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group V</intervention_name>
    <description>0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.</description>
    <arm_group_label>group V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group LV</intervention_name>
    <description>10% Lidocaine was applied on laryngoscope blade and trachea.</description>
    <arm_group_label>group LV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 20-60 years,

          -  ASA groups I or II

        Exclusion Criteria:

          -  ASA III or IV,

          -  hypertension,

          -  anticipated difficult airway, and

          -  severe coronary and cerebrovascular diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SUE YOUNG LEE, MD</last_name>
    <phone>82-10-9700-6509</phone>
    <email>tndude49@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee-Pyoung PARK, MD PhD</last_name>
      <phone>82-2-2072-2466</phone>
      <email>hppark@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hee-Pyung Park, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 26, 2012</lastchanged_date>
  <firstreceived_date>November 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee-Pyoung Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
